Literature DB >> 9217248

Bioavailability and metabolism of cidofovir following topical administration to rabbits.

K C Cundy1, G Lynch, W A Lee.   

Abstract

The bioavailability and metabolism of the antiviral nucleotide analog cidofovir (HPMPC) were examined in New Zealand white rabbits following topical administration to normal and abraded skin. Male rabbits (four per group) received 14C-cidofovir (100 microCi/kg) intravenously (1 mg/kg) as a solution or topically (2 mg/animal) as a 1% w/w gel containing hydroxyethylcellulose (HEC) with or without propylene glycol (PG). The same PG/HEC formulation was applied topically to an abraded skin site in a fourth group of animals. All radioactivity detected in plasma and skin was accounted for by cidofovir. Plasma concentrations of radioactivity declined multiexponentially following intravenous administration, with a terminal half-life of 5.4 h. For intact skin, the absolute bioavailabilities of the HEC and PG/HEC formulations were 0.2 and 2.1%, respectively. For abraded skin, the bioavailability for the PG/HEC gel was 41%. Radioactivity in kidneys was attributed to cidofovir ( > 95%) and cyclic HPMPC. Concentrations in kidney following topical administration of cidofovir to normal skin were < 4% of those following intravenous dosing. Topical application of cidofovir to intact skin led to negligible systemic exposure to the drug. The topical bioavailability and hence the flux of cidofovir through intact skin was enhanced by the presence of PG in the formulation. Abrasion of the skin removed the principal barrier to absorption and led to significant systemic exposure to cidofovir.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217248     DOI: 10.1016/s0166-3542(97)00022-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

1.  Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.

Authors:  J A Johnson; J D Gangemi
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir.

Authors:  Leslie Castelo-Soccio; Ronald Bernardin; John Stern; Stephen A Goldstein; Carrie Kovarik
Journal:  Arch Dermatol       Date:  2010-02

4.  Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Authors:  E Bart Tarbet; Deanna Larson; Bentley J Anderson; Kevin W Bailey; Min-Hui Wong; Donald F Smee
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

5.  Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.

Authors:  Chad J Roy; Robert Baker; Kenneth Washburn; Mike Bray
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

7.  Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability.

Authors:  Shweta Gupta; Rajesh Kesarla; Narendra Chotai; Ambikanandan Misra; Abdelwahab Omri
Journal:  Biomed Res Int       Date:  2017-01-23       Impact factor: 3.411

8.  Development and validation of reversed-phase HPLC gradient method for the estimation of efavirenz in plasma.

Authors:  Shweta Gupta; Rajesh Kesarla; Narendra Chotai; Abdelwahab Omri
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

9.  Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.

Authors:  Debra C Quenelle; Deborah J Collins; Earl R Kern
Journal:  Antiviral Res       Date:  2004-07       Impact factor: 10.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.